euctr_id,title,member_state,trial_status,sponsor_name,sponsor_status,sponsor_country,funder,reg_date,row
2020-002510-40,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",Germany - PEI,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Innate Pharma,2020-10-08,1
2020-002282-33,Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),Germany - BfArM,Prematurely Ended,Charité - Universitaetsmedizin Berlin,Non-Commercial,Germany,Bayer AG,2020-05-29,1
2017-004458-41,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",Germany - PEI,Completed,Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie,Non-Commercial,Germany,Sanofi-Aventis Deutschland GmbH,2018-07-09,1
2017-001604-30,"Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",Austria - BASG,Completed,Medical University of Vienna,Non-Commercial,Austria,Medical University of Vienna,2017-09-29,1
2017-001604-30,"Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",Germany - PEI,Completed,Charité Berlin,Non-Commercial,Germany,Charité Berlin,2018-02-06,2
2016-004825-17,A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,BMBF,2017-11-09,1
2016-003828-23,A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS) ,Germany - PEI,Completed,Charité - Universitätsmedizin Berlin; Dpt. of Dermatology and Allergy,Non-Commercial,Germany,ROCHE/CHUGAI Pharma AG,2017-01-31,1
2016-002370-12,PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,Germany - PEI,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Baxalta GmbH,2016-07-21,1
2016-001777-33,EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Charité Universitätsmedizin Berlin,2016-06-06,1
2016-000615-33,Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),Germany - PEI,Completed,Charite Universitaetsmedizin,Non-Commercial,Germany,Federal Ministry of Education and Research,2016-07-06,1
2015-005346-58,Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),Germany - PEI,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Biodrim Consortium,2016-08-05,1
2015-005346-58,Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),Czech Republic - SUKL,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Biodrim Consortium,2016-08-18,2
2015-005346-58,Tacrolimus after rATG and infliximab induction immunosuppression,Spain - AEMPS,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Biodrim Consortium,2017-02-28,3
2015-001456-29,"A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD)",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Bundeministerium für Bildung und Forschung (BMBF),2015-07-08,1
2015-000538-31,NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,Germany - BfArM,Completed,Charité University medicine Berlin,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung,2015-04-07,1
2015-000465-31,"Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2016-03-30,1
2014-005344-17,"Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",Germany - BfArM,Completed,"Department of Anesthesiology and Operative Intensive Care Medicine, Charité (CBF)",Non-Commercial,Germany,EU-commission,2015-01-02,1
2014-005239-15,Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2016-02-03,1
2014-004551-32,Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety,Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Bristol-Myers-Squibb,2015-08-28,1
2014-002392-28,Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,Germany - BfArM,Completed,Charité Univeritaetsmedizin Berlin,Non-Commercial,Germany,"Funds of the Institute of Experimental Pediatric Endocrinology, Charité Universitaetsmedizin Berlin",2014-08-04,1
2014-001551-22,Reduction of postoperative wound infections by antiseptica,Germany - BfArM,Completed,Charité Universitätsmedizin,Non-Commercial,Germany,Charité Universitätsmedizin,2014-06-18,1
2014-000181-21,"Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",Germany - BfArM,Completed,Charite - Universitätsmedizin Berlin,Non-Commercial,Germany,FAES FARMA,2014-04-23,1
2013-005362-19,Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Deutsche Forschungsgemeinschaft,2013-12-18,1
2013-004130-15,"Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",Germany - BfArM,Completed,"Charité-Universitätsmedizin Berlin, Department of Dermatology, Clinical Research Center for Hair and Skin Science",Non-Commercial,Germany,Clinical Research Center for Skin and Hair Science (CRC),2014-03-05,1
2013-003601-25,"A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2013-11-12,1
2013-002409-75,"Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",Germany - BfArM,Completed,Charite,Non-Commercial,Germany,Bayer AG,2013-08-23,1
2013-000823-15,Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,Germany - BfArM,Completed,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,Charité – Universitaetsmedizin Berlin,2013-11-19,1
2013-000416-24,THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),Germany - BfArM,Completed,"Charité-Universitätsmedizin Berlin, Department of Dermatology, Clinical Research Center for Hair and Skin Science",Non-Commercial,Germany,European Centre for Allergy Research Foundation,2013-04-08,1
2012-005726-30,"A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",Germany - PEI,Completed,Charité - Universitätsmedizin,Non-Commercial,Germany,"Regeneron Pharmaceuticals, Inc",2013-05-29,1
2012-005652-42,Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,Germany - PEI,Completed,"Charité, Universitätsmedizin Berlin",Non-Commercial,Germany,Bristol-Myers Squibb GmbH & Co. KGaA,2013-06-12,1
2012-004111-32,"Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Galderma International SAS,2012-11-09,1
2012-003943-32,Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,Germany - PEI,Prematurely Ended,Charité University Medicine Berlin,Non-Commercial,Germany,Charité University Medicine Berlin,2015-03-31,1
2012-003882-17,"Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",Germany - BfArM,Completed,Charité Universitaetsmedizin Berlin,Non-Commercial,Germany,Volkswagen Foundation,2013-04-08,1
2012-003621-21,"Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",Germany - BfArM,Completed,Charité University Hospital Berlin,Non-Commercial,Germany,Novartis Pharma GmbH,2013-06-06,1
2012-003217-33,"Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,HEYL Chem.-pharm. Fabrik GmbH & Co. KG,2012-08-13,1
2012-000443-27,Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,Germany - BfArM,Prematurely Ended,"Dept. of Anesthesiology and Intensive Care, Charité - Campus Benjamin Franklin",Non-Commercial,Germany,"Dept. of Anesthesiology and Intensive Care, Charité - Campus Benjamin Franklin",2012-03-19,1
2012-000411-91,"Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2012-12-04,1
2012-000188-25,Lormetazepam versus Midazolam used as sedatives for critically ill patients.,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2013-03-14,1
2011-005615-87,"A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",Germany - PEI,Completed,"Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin",Non-Commercial,Germany,Novartis Pharma,2012-07-24,1
2011-004944-23,,Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin,Non-Commercial,Germany,Atellas Pharma GmbH,2011-12-05,1
2011-004787-30,Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,Germany - BfArM,Prematurely Ended,Charite Universitaetsmedizin Berlin,Non-Commercial,Germany,Charite Universitaetsmedizin Berlin,2012-07-13,1
2011-004585-15,"Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes",Germany - PEI,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Fresenius Biotech GmbH,2012-09-06,1
2011-004463-69,Investigation of Radiation Retinopathy (RadiRet Study),Germany - PEI,Prematurely Ended,Charité – University Medicine Berlin,Non-Commercial,Germany,Novartis Pharma,2012-08-03,1
2011-004393-28,"""Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study""",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Karl und Veronika Carstens Stiftung Essen,2011-12-09,1
2011-004094-93,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",Germany - BfArM,Completed,Allergie-Centrum Charité,Non-Commercial,Germany,"J. Uriach Cia., S.A.",2012-01-27,1
2011-004094-93,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40 mg in cold contact urticaria (CCU)",Spain - AEMPS,Completed,Consorci Mar Parc de Salut de Barcelona,Non-Commercial,Spain,"J. Uriach y Compañía, S.A.",2012-02-21,2
2011-003746-41,"A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",Germany - PEI,Prematurely Ended,"Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin",Non-Commercial,Germany,Novartis Pharma,2011-11-28,1
2011-002785-20,Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2011-08-11,1
2011-001689-16,"Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Federal Ministry of Education and Research,2013-02-04,1
2011-001474-25,"A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",Germany - BfArM,Prematurely Ended,"Klinik für Dermatologie, Venerologie und Allergologie; Charité - Universitätsmedizin Berlin",Non-Commercial,Germany,"AG Voit (Research fund, administered by Prof. Christiane Voit)",2011-09-20,1
2011-001403-12,Carbon Dioxide for the Treatment of Febrile Seizures,Germany - BfArM,Prematurely Ended,Charite Universitaetsmedizin Berlin,Non-Commercial,Germany,Charite Universitaetsmedizin Berlin - NeuroCure,2011-10-28,1
2011-001398-19,D-cycloserine augmented exposure therapy in patients with agoraphobia,Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2011-05-30,1
2011-001232-27,Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,Germany - BfArM,Completed,Charité Universitaetsmedizin Berlin,,Germany,NA,2011-12-27,1
2011-001027-20,"A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",Germany - PEI,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Novartis Pharma GmbH,2011-12-05,1
2011-000844-56,"UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",Germany - PEI,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Janssen-Cilag,2011-06-09,1
2010-024379-15,"Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study. - The PaFLO study.",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2011-07-20,1
2010-024156-28,"A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",Germany - PEI,Completed,Charité - University Hospital of Berlin,Non-Commercial,Germany,Novartis Pharma GmbH,2011-04-07,1
2010-023941-31,Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington,Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Charité Universitätsmedizin Berlin,2011-03-17,1
2010-023044-32,Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder,Germany - BfArM,Completed,Charité Universitaetsmedizin Berlin,Non-Commercial,Germany,NA,2011-03-21,1
2010-021861-62,Baclofen for the Treatment of Alcohol Dependence,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-09-16,1
2010-021775-80,Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,Germany - PEI,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-09-14,1
2010-021604-16,"A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Charité Universitätsmedizin Berlin,2010-10-13,1
2010-021275-92,"Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",Germany - BfArM,Completed,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-10-01,1
2010-021001-21,"An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",Germany - BfArM,Completed,Allergie-Centrum-Charité,Non-Commercial,Germany,NA,2010-06-16,1
2010-020480-21,Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,Germany - BfArM,Completed,Universitätsmedizin Charite,Non-Commercial,Germany,NA,2010-07-28,1
2010-020433-13,"Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie",Germany - BfArM,Prematurely Ended,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-11-26,1
2010-020063-21,"“A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",Germany - PEI,Completed,Charité-Universitätsmedizin,Non-Commercial,Germany,NA,2010-05-21,1
2010-019347-18,"Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-04-20,1
2010-019344-39,"Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU) Compound: Bilastine",Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-04-15,1
2010-019218-26,Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,Germany - BfArM,Completed,Charité - University Hospital of Berlin,Non-Commercial,Germany,NA,2010-12-22,1
2010-018291-25,"INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",Germany - BfArM,Completed,"Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, CRC",Non-Commercial,Germany,"Medical grant application, Johnson & Johnson Consumer Co Inc",2010-06-24,1
2009-017739-17,Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,Germany - BfArM,Completed,Charité,Non-Commercial,Germany,NA,2010-01-04,1
2009-017581-22,Cognitive impairment in bipolar disorder treated with aripiprazole,Germany - BfArM,Completed,"Department of Psychiatry and Psychotherapy, Charity University Medicine",Non-Commercial,Germany,NA,2010-12-07,1
2009-017458-11,"Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",Germany - BfArM,Prematurely Ended,"Institute for Social Medicine, Epidemiology, and Health Economics, Charité Berlin",Non-Commercial,Germany,NA,2010-03-24,1
2009-016907-41,"Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",Germany - BfArM,Completed,"Charité, Universitätsmedizin Berlin",Non-Commercial,Germany,Deutsche Forschungsgemeinschaft,2012-08-13,1
2009-016482-28,SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,Germany - BfArM,Prematurely Ended,Charite Universitätsmedizin Berlin,Non-Commercial,Germany,aktion benni & co.,2010-03-15,1
2009-016043-19,Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,Germany - BfArM,Completed,Charité – University Medicine Berlin,Non-Commercial,Germany,NA,2010-02-09,1
2009-015319-41,Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),Germany - BfArM,Prematurely Ended,Charite Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2011-02-04,1
2009-014300-55,"Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",Germany - BfArM,Prematurely Ended,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-12-10,1
2009-013976-38,Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),Germany - BfArM,Completed,"Charité Berlin, Department of rheumatology",Non-Commercial,Germany,NA,2009-12-07,1
2009-013458-33,Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-09-21,1
2009-013432-20,"Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",Germany - BfArM,Completed,Charité Campus Mitte,Non-Commercial,Germany,NA,2009-06-22,1
2009-011922-33,"A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-10-14,1
2009-009656-20,Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease,Germany - BfArM,Prematurely Ended,Charite Universitaetsmedizin Berlin,Non-Commercial,Germany,NA,2009-03-13,1
2009-009476-12,Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,Germany - BfArM,Completed,"Charité Campus Mitte, Instituts für Radiologie",Non-Commercial,Germany,NA,2009-05-28,1
2008-008474-31,Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,Germany - BfArM,Completed,Charité Berlin,Non-Commercial,Germany,NA,2009-06-26,1
2008-008232-87,Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,Germany - BfArM,Prematurely Ended,Charite Universitätsmedizin Berlin- Campus Virchow-Klinikum,Non-Commercial,Germany,NA,2009-03-09,1
2008-007237-47,Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2008-11-19,1
2008-007031-41,"Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",Germany - BfArM,Prematurely Ended,Center for Stroke Research Berlin - Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-09-14,1
2008-006135-12,Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,Germany - BfArM,Completed,Charité- University Medicine Berlin,Non-Commercial,Germany,NA,2008-11-11,1
2008-005786-60,"A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours",Germany - BfArM,Prematurely Ended,Charité Universitaetsmedizin Berlin,Non-Commercial,Germany,Deutsche Kinderkrebsstiftung,2014-01-14,1
2008-005746-22,"Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",Germany - BfArM,Completed,"Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin",Non-Commercial,Germany,NA,2009-01-26,1
2008-005451-23,"Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",Germany - BfArM,Prematurely Ended,"Charité - Universitätsmedizin Berlin, CharitéCentrum 3 für Zahn-, Mund- und Kieferheilkunde",Non-Commercial,Germany,NA,2009-01-26,1
2008-005213-22,SUPREMES - Sunphenon in progressive forms of multiple sclerosis,Germany - BfArM,Completed,Charite Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-08-22,1
2008-005167-33,Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,Germany - BfArM,Completed,Charité University Medicine Berlin,Non-Commercial,Germany,NA,2010-03-16,1
2008-004182-26,"Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-02-02,1
2008-003256-29,Effect of Methylnaltrexone on Postoperative Analgesic Demands,Germany - BfArM,Completed,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,International Anesthesia Research Society,2009-01-20,1
2008-002226-11,Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,Germany - BfArM,Completed,Charité - Unversitätsmedizin Berlin,Non-Commercial,Germany,Bundesministerium für Bildung und Forschung,2008-09-03,1
2008-001849-26,"Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus.",Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-07-29,1
2008-001770-33,"INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME",Germany - BfArM,Completed,"Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, CRC",Non-Commercial,Germany,NA,2008-04-22,1
2008-000653-36,Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-05-27,1
2008-000247-34,Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom (Prospective randomized phase II/III study for the selective COX-2-inhibition in chronic subdural haematoma),Germany - BfArM,Prematurely Ended,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-08-05,1
2007-007657-31,Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,Germany - BfArM,Completed,Charité-University Berlin,Non-Commercial,Germany,NA,2008-02-26,1
2007-007637-39,Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2,Germany - BfArM,Completed,Charité - Campus Mitte,Non-Commercial,Germany,NA,2008-04-15,1
2007-007011-85,Topical application of morphine for wound healing and analgesia in patients with painful oral lesions,Germany - BfArM,Completed,Charite Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2010-01-29,1
2007-006438-33,Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-04-22,1
2007-006126-10,pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,Germany - PEI,Prematurely Ended,Charité - University Hospital Berlin,Non-Commercial,Germany,NA,2008-07-22,1
2007-005475-34,Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-03-03,1
2007-004674-49,Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-10-30,1
2007-004401-10,"Hydrocortisone for Prevention of Septic Shock Placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of low dose hydrocortisone to prevent the development of septic shock in patients with severe sepsis",Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Federal Ministry of Education and Research,2008-02-28,1
2007-004150-85,Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors,Germany - BfArM,Prematurely Ended,Charité Universitaetsmedizin Berlin,Non-Commercial,Germany,NA,2007-12-04,1
2007-004134-16,Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom,Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-02-16,1
2007-003813-15,"CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte, Phase III Studie",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-10-26,1
2007-003775-39,"Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",Germany - BfArM,Prematurely Ended,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-09-09,1
2007-003111-31,Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,Germany - PEI,Completed,Charité - Universitaetsmedizin Berlin,Non-Commercial,Germany,Charité - Universitaetsmedizin Berlin,2008-05-16,1
2007-002967-28,Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,Germany - PEI,Completed,Charité University Medicine,Non-Commercial,Germany,NA,2007-08-24,1
2007-002223-32,"A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",Germany - BfArM,Completed,Charité Universitaetsmedizin,Non-Commercial,Germany,NA,2008-02-07,1
2007-002223-32,"A multicentre, double-blind, randomised controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",Ireland - HPRA,Prematurely Ended,Charité Universitaetsmedizin,Non-Commercial,Germany,NA,2009-03-26,2
2007-002023-32,Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-06-04,1
2007-001787-71,The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-12-17,1
2007-001677-28,"Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-07-02,1
2007-001677-28,Evaluation de l’effet anesthésique du protoxyde d’azote dans une population d’opérés recevant une anesthésie totale intraveineuse en « boucle » guidée par l’index bispectral (Effect of nitrous oxide on intra-venous closed-loop anesthesia),France - ANSM,Completed,Hopital Foch,Non-Commercial,France,NA,2007-07-23,2
2007-001677-28,Evaluation de l’effet anesthésique du protoxyde d’azote dans une population d’opérés recevant une anesthésie totale intraveineuse en « boucle » guidée par l’index bispectral (Effect of nitrous oxide on intra-venous closed-loop anesthesia),Belgium - FPS Health-DGM,Completed,Hopital Foch,Non-Commercial,France,NA,2007-11-13,3
2007-000718-35,"CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-10-18,1
2007-000579-40,"Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-10-02,1
2007-000512-82,"Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-08-15,1
2006-006516-30,Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,Germany - BfArM,Completed,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-04-18,1
2006-006323-39,Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,Germany - BfArM,Completed,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-03-05,1
2006-006088-22,Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction,Germany - BfArM,Completed,"Klinik für Chirurgie, Charité Campus Virchow-Klinikum",Non-Commercial,Germany,Deutsche Krebshilfe,2011-02-14,1
2006-005710-12,Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-06-18,1
2006-005262-39,Flupirtin as Oral Treatment in MS,Germany - BfArM,Completed,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-03-09,1
2006-004891-10,Future strategies for vocational rehabilitation schizophrenia,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2006-11-22,1
2006-004860-29,D-Cycloserine supported exposure in panic disorder,Germany - BfArM,Completed,Charité- Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2006-12-07,1
2006-004628-34,"Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2006-12-15,1
2006-004628-34,"Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",Austria - BASG,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-12-04,2
2006-004290-97,"A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",Germany - PEI,Completed,"Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy",Non-Commercial,Germany,NA,2006-10-17,1
2006-004162-13,"Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",Germany - BfArM,Prematurely Ended,"Charité Universitätsmedizin, Campus Charité Mitte",Non-Commercial,Germany,NA,2006-10-06,1
2006-003999-35,Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients,Germany - BfArM,Completed,"Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie",Non-Commercial,Germany,NA,2006-10-10,1
2006-003686-13,"An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",Germany - BfArM,Completed,"Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin",Non-Commercial,Germany,NA,2007-03-29,1
2006-003470-10,Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,Germany - BfArM,Completed,"Charité Universitätsmedizin Berlin, Campus Benjamin Franklin",Non-Commercial,Germany,NA,2007-03-06,1
2006-003146-41,A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,Germany - PEI,Completed,Charité-Universitätsmedizin Berlin; Department of Rheumatology and Clinical Immunology,Non-Commercial,Germany,NA,2006-11-23,1
2006-002306-64,Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,Germany - PEI,Completed,Charité Universitaetsmedizin,Non-Commercial,Germany,NA,2006-10-04,1
2006-001528-38,Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive,Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2006-10-17,1
2006-000815-24,A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses – a single center study,Germany - BfArM,Prematurely Ended,Charité,Non-Commercial,Germany,NA,2006-05-16,1
2005-006133-32,"An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",Germany - BfArM,Completed,Allergie-Centrum-Charité,Non-Commercial,Germany,NA,2006-06-28,1
2005-005021-60,"Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",Germany - BfArM,Completed,Prof. Dr. R. Kreutz Leiter der Abteilung Klinische Pharmakologie der Charite Berlin,Non-Commercial,Germany,NA,2006-12-05,1
2005-005017-38,Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,Germany - PEI,Completed,"Charité Berlin, CBF",Non-Commercial,Germany,NA,2006-06-21,1
2005-003714-15,Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,Germany - BfArM,Completed,"Charite CBF, Endokrinologie",Non-Commercial,Germany,NA,2005-09-28,1
2005-003648-70,"Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2007-02-20,1
2005-003617-33,A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze,Germany - BfArM,Completed,Charité,Non-Commercial,Germany,NA,2006-05-22,1
2005-003488-22,Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,Germany - BfArM,Completed,"Charité CBF, Endokrinologie",Non-Commercial,Germany,NA,2006-05-22,1
2005-003195-38,Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate 150 mg on structural properties of bone in postmenopausal osteoporosis without vertebral fractures,Germany - BfArM,Completed,Center for Muscle and Bone Research of the Charité Universitaetsmedizin Berlin,Non-Commercial,Germany,NA,2005-09-12,1
2005-002582-37,"Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients",Germany - BfArM,Completed,Allergie-Centrum-Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2005-10-28,1
2005-002475-32,"Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",Germany - BfArM,Prematurely Ended,Charitè Universitätmeditin Berlin,Non-Commercial,Germany,NA,2006-05-16,1
2005-002320-34,Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Pfizer Germany,2006-05-16,1
2005-001907-21,"A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",Germany - BfArM,Prematurely Ended,"Klinik für Anästhesiologie und operative Intensivmedizin, Charité – Universitätsmedizin Berlin",Non-Commercial,Germany,NA,2005-06-24,1
2005-001602-76,Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression.,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2006-01-09,1
2005-001559-39,Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,Germany - BfArM,Completed,Charité-Campus Mitte und Campus Virchow-Klinikum,Non-Commercial,Germany,NA,2006-06-02,1
2005-001486-33,Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome [Sicherheit und Wirksamkeit von Levetiracetam (Keppra) für die Behandlung des stationären Alkoholentzugsyndroms],Germany - BfArM,Completed,"Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie",Non-Commercial,Germany,NA,2005-06-15,1
2005-001456-20,„Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2005-11-22,1
2004-005172-17,Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,Germany - BfArM,Completed,"Charité/Campus Virchow-Klinikum, Medizinische Klinik m. S. Kardiologie",Non-Commercial,Germany,NA,2006-05-22,1
2004-004352-40,Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,Germany - PEI,Completed,"Kliniken für Anästhesiologie und op. Intensivmedizin, Charité – Universitätsmedizin Berlin, CVK/CCM",Non-Commercial,Germany,NA,2004-11-30,1
2004-003816-47,Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,Germany - BfArM,Completed,"Pädiatrische Endokrinologie, Universitätsmedizin Berlin, Charité",Non-Commercial,Germany,NA,2005-10-19,1
2004-000957-47,Comparison of Bisoprolol and Carvedilol in elderly patients with heart failure. A randomised doubleblind multicenter trial,Slovenia - JAZMP,Completed,Charité,Non-Commercial,Germany,NA,2007-11-08,1
2021-006176-16,Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),Germany - PEI,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Lilly Deutschland GmbH,2022-04-04,1
2021-006031-25,Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),Germany - BfArM,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Abbvie,2022-04-05,1
2021-002245-15,A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,Germany - PEI,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2021-04-30,1
2021-001512-28,Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,Germany - PEI,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,BMBF,2021-04-13,1
2021-000962-14,"A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",Germany - PEI,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,JANSSEN-CILAG GmbH,2021-04-19,1
2021-000613-16,"CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial",Germany - BfArM,Prematurely Ended,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,Bayer AG,2021-09-08,1
2021-000319-21,Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),Germany - BfArM,Ongoing,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,Federal Ministry of Education and Research (BMBF),2021-07-01,1
2020-006144-18,"Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer",Germany - BfArM,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,DFG - Deutsche Forschungsgemeinschaft e.V.,2021-04-29,1
2020-004399-16,"Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",Germany - PEI,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Novartis Pharma GmbH,2021-02-23,1
2020-004102-63,"AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",Germany - BfArM,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Charité Universitätsmedizin Berlin,2020-11-12,1
2020-001493-29,Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,Germany - BfArM,Prematurely Ended,Charité - Universitaetsmedizin Berlin,Non-Commercial,Germany,Charité - Universitaetsmedizin Berlin,2020-04-14,1
2019-004223-20,"Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",Germany - BfArM,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Servier,2021-03-30,1
2019-001235-31,Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930),Germany - PEI,Ongoing,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,Shire International GmbH,2019-11-11,1
2018-004254-22,"Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (PASTOR)",Germany - BfArM,Ongoing,Charite University,Non-Commercial,Germany,"Pfizer Pharma GmbH, unrestricted grant",2019-06-25,1
2018-004136-30,"An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical signs and symptoms of Hereditary angioedema with normal C1-inhibitor",Germany - PEI,Ongoing,Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie,Non-Commercial,Germany,Shire International GmbH,2019-03-14,1
2018-002947-27,"Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",Germany - BfArM,Ongoing,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,Charité – Universitätsmedizin Berlin,2019-03-07,1
2018-002938-20,Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,Germany - PEI,Completed,Charite - Universitätsmedizin Berlin,Non-Commercial,Germany,Merck KGaA,2018-12-03,1
2018-000492-32,"Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections",Germany - BfArM,Prematurely Ended,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,Deutsche Forschungsgemeinschaft,2018-09-19,1
2017-005151-83,INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,Germany - PEI,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Janssen-Cilag GmbH,2018-07-09,1
2017-004149-26,Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,Germany - BfArM,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,DZHK,2018-03-21,1
2017-003813-24,"A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",Germany - BfArM,Ongoing,Charité-Universitätsmedizin Berlin,Non-Commercial,Germany,BMBF,2018-05-02,1
2017-002124-24,Oral Propranolol for prevention of threshold retinopathy of prematurity,Germany - BfArM,Restarted,Universität Zürich,Non-Commercial,Switzerland,DFG and BMBF (BMBF/ DLR Projektträger),2017-09-25,1
2017-001262-25,"A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",Germany - PEI,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Sanofi-Aventis Deutschland GmbH,2018-08-06,1
2017-000697-11,"SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction",Germany - BfArM,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,DZHK - Deutsches Zentrum für Herz-Kreislauf-Forschung,2017-12-08,1
2017-000697-11,"SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction",Austria - BASG,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,DZHK - Deutsches Zentrum für Herz-Kreislauf-Forschung,2019-06-04,2
2017-000697-11,"SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction",France - ANSM,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,DZHK - Deutsches Zentrum für Herz-Kreislauf-Forschung,2019-08-01,3
2017-000058-21,Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,Germany - BfArM,Restarted,"Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin",Non-Commercial,Germany,Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.,2017-08-28,1
2016-003802-14,Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,Germany - BfArM,Prematurely Ended,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité - Universitätsmedizin Berlin,2016-10-14,1
2016-003175-22,Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP-- DuTRe-raD,Germany - PEI,Ongoing,Charite Universitätsmedizin Berlin,Non-Commercial,Germany,Charité Comprehensive Cancer Center,2017-11-13,1
2015-005757-12,"Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency with and without anaemia",Germany - BfArM,Prematurely Ended,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,Vifor Pharma,2017-05-02,1
2015-004172-30,"Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity",Germany - BfArM,Ongoing,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,Charité – Universitätsmedizin Berlin,2021-04-16,1
2015-003429-32,"“Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",Germany - BfArM,Ongoing,Charité - Universitätsmedizin Berlin,Commercial,Germany,Janssen-Cilag GmbH,2016-08-19,1
2015-003429-32,"“Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",Austria - BASG,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Janssen-Cilag GmbH,2020-04-03,2
2014-003457-34,"Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",Germany - PEI,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Charité Universitätsmedizin Berlin,2018-07-27,1
2014-002439-32,A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma,Germany - BfArM,Ongoing,Charité – Universitätsmedizin Berlin,Non-Commercial,Germany,Sirtex Medical Inc,2015-02-13,1
2014-000097-19,"Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",Germany - BfArM,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2016-01-12,1
2013-001599-40,"Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,DFG (BMBF),2013-11-14,1
2013-001294-24,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,Germany - PEI,Completed,Medizinischen Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin/Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,European Commission,2014-04-24,1
2012-001209-26,Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,Germany - BfArM,Restarted,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,ARISTO Pharma GmbH,2013-09-17,1
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Sweden - MPA,,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-02-01,1
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Germany - BfArM,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-02-09,2
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Denmark - DHMA,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-02-11,3
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Portugal - INFARMED,,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-03-01,4
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Austria - BASG,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-03-03,5
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Norway - NOMA,,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-03-14,6
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Finland - Fimea,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-04-22,7
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,France - ANSM,,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-04-26,8
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Czech Republic - SUKL,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2016-09-21,9
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Belgium - FPS Health-DGM,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2017-05-30,10
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Spain - AEMPS,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2017-08-10,11
2012-000810-12,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,Netherlands - Competent Authority,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,EU Project FP7,2020-01-06,12
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Sweden - MPA,Completed,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2012-12-17,1
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Portugal - INFARMED,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2012-12-19,2
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010.,UK - MHRA,GB - no longer in EU/EEA,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2012-12-19,3
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Germany - PEI,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2012-12-19,4
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Belgium - FPS Health-DGM,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2012-12-20,5
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Austria - BASG,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2013-01-14,6
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Ireland - HPRA,Completed,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2013-01-22,7
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Finland - Fimea,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2013-02-19,8
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Denmark - DHMA,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2013-02-25,9
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Czech Republic - SUKL,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2013-03-15,10
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Italy - Italian Medicines Agency,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2013-07-04,11
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Netherlands - Competent Authority,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2014-10-14,12
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 - A randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group,France - ANSM,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2015-08-07,13
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010. A randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group.,Poland - Office for Medicinal Products,,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2017-07-07,14
2012-000793-30,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,Spain - AEMPS,Ongoing,Charité - University Hospital of Berlin,Non-Commercial,Germany,EU Project FP7,2018-11-05,15
2011-000259-17,A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Novartis Pharma GmbH,2011-12-07,1
2009-014844-13,Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,Germany - BfArM,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-12-29,1
2009-011277-33,A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,Germany - BfArM,Completed,Charité - University Hospital of Berlin,Non-Commercial,Germany,NA,2009-05-26,1
2009-009928-37,Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie,Germany - BfArM,Completed,Charite Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-08-12,1
2008-006055-52,Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,Germany - BfArM,Prematurely Ended,Charité - University Hospital of Berlin,Non-Commercial,Germany,NA,2008-11-17,1
2007-003642-15,"A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",Germany - PEI,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2008-01-24,1
2007-003370-26,"A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",Germany - BfArM,Ongoing,Charite Universitätsmedizin Berlin,Non-Commercial,Germany,NA,2009-06-18,1
2006-006962-41,Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,Germany - PEI,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Novartis,2007-08-13,1
2006-001269-40,Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Therapy,Germany - PEI,Ongoing,Charité University Medicine,Non-Commercial,Germany,NA,2008-03-11,1
2004-002646-35,Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,Germany - BfArM,Completed,"Franz Volhard Clinic, Charite Campus Buch",Non-Commercial,Germany,NA,2006-05-08,1
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",France - ANSM,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Astellas Europe (unrestricted grant),2018-05-03,1
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",UK - MHRA,GB - no longer in EU/EEA,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Astellas Europe (unrestricted grant),2018-05-22,2
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",Austria - BASG,Prematurely Ended,"Charité Universitätsmedizin Berlin, Medizinische Klinik m.S. Nephrologie",Non-Commercial,Germany,Astellas Europe (unrestricted grant),2018-07-16,3
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",Spain - AEMPS,Prematurely Ended,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Astellas Europe (unrestricted grant),2018-08-02,4
2014-002643-18,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",Denmark - DHMA,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,Astellas Europe (unrestricted grant),2018-08-17,5
2014-001325-33,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,Germany - BfArM,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Biodrim Consortium,2015-02-20,1
2014-001325-33,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,Spain - AEMPS,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Biodrim Consortium,2015-03-03,2
2014-001325-33,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,Czech Republic - SUKL,Completed,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Biodrim Consortium,2015-07-24,3
2014-001325-33,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,Netherlands - Competent Authority,Ongoing,Charité - Universitätsmedizin Berlin,Non-Commercial,Germany,Biodrim Consortium,2015-09-29,4
2013-003542-17,"A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",Germany - BfArM,Completed,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,GA²LEN e.V.,2014-04-07,1
2013-003542-17,"A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",Spain - AEMPS,Ongoing,Charité Universitätsmedizin Berlin,Non-Commercial,Germany,GA²LEN e.V.,2014-10-16,2
2007-007034-18,Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,Germany - PEI,Completed,Charité Universitätsmedizin Berlin - CVK,Non-Commercial,Germany,NA,2008-08-15,1
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,Germany - PEI,Completed,"Charité-Universitätsmedizin Berlin, Germany",Non-Commercial,Germany,NA,2007-01-05,1
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III-IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease.,Sweden - MPA,Ongoing,Charite-Universitätsmedizin Berlin Germany,Non-Commercial,Germany,NA,2007-04-13,2
2006-005778-34,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,Austria - BASG,Completed,"Charité-Universitätsmedizin Berlin, Germany",Non-Commercial,Germany,NA,2007-04-25,3
2004-002420-18,"A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",Germany - BfArM,Completed,"Prof. B. Wiedenmann, Klinik für Gastroenterologie, Charité, Campus Virchow",Non-Commercial,Germany,NA,2005-02-11,1
2004-002420-18,"A prospective, non-randomised, non-controlled, open label, multicentre phase II study: PTK 787/ZK222584 in patients with advanced neuroendocrine tumours",UK - MHRA,GB - no longer in EU/EEA,CHARITE Universitätsmedizin Berlin Campus Virchow-Klinikum,Non-Commercial,Germany,NA,2005-03-16,2
